TriVascular Technologies Inc

TriVascular Technologies — Merger or Acquisition (October 2015)

13 slides from TriVascular Technologies's merger presentation, Oct 28, 2015

  1. Slide 1: Endologix Third Quarter 2015 Results and TriVascular Merger

    Combining innovation leaders to revolutionize aortic treatments Endologix Third Quarter 2015 Results and TriVascular Merger October 26, 2015 Filed by Endologix, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934

  2. Slide 2: Safe Harbor

    Safe Harbor Endologix and TriVascular will remain separate operational entities until the closing of the proposed merger transaction. Until closing, Endologix will not offer TriVascular products and TriVascular will not offer Endologix products. Forward-Looking Statements This presentation includes

  3. Slide 3: Endologix 3Q 2015 Results

    Endologix 3Q 2015 Results Revenue of $38.2 million, up 7% in constant currency Nellix® system sales increased 45% in Europe Nellix US IDE Continued Access approval for additional 50 patients Nellix approval in Argentina AFX2® FDA approval Combining innovation leaders to revolutionize aortic treatmen

  4. Slide 4: Merger Rationale

    Merger Rationale Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Expanded global sales force Broad product offering for AAA Multiple new product launches over next 24 months An innovation leader with broad clinical indications Significant clinical evidence 370 issued and p

  5. Slide 5: Strong Revenue Growth With A Combined CAGR of 8%

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Strong Revenue Growth With A Combined CAGR of 28% Revenue $millions 180 152 111 89

  6. Slide 6: Innovative Products With Broad Clinical Indications

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 EVAR Innovative Products With Broad Clinical Indications (post merger) Low profile Narrow & tortuous iliacs Complex necks Reverse taper Preserve bifurcation Tight distal aorta Thrombus EVAS Complete AAA sealing Iliac aneurysm

  7. Slide 7: Significant Clinical Evidence To Drive Adoption

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Significant Clinical Evidence To Drive Adoption* (post merger) 2015 2016 2017 Ovation IDE/CAP/PAS (2010) 320 320 320 Global Registry (2011) 501 501 501 LIFE (2014) 200 250 250 LUCY (2015) 20 225 225 Total 1,041 1,296 1,296 AF

  8. Slide 8: Diversified Product Revenue

    Diversified Product Revenue (post merger) Combining innovation leaders to revolutionize aortic treatments | 10.26.15 Total Revenue: $190 million Q4 2014 – Q3 2015 AFX 68% Ovation 19% Nellix 13% U.S. 70% International 30% Revenue by geography Revenue by product

  9. Slide 9: Expanded Global Sales Force

    Expanded Global Sales Force (post merger) World-class team of trained sales representatives and clinical specialists Significant growth and cross-selling opportunities Customers in 44 countries across five continents Both Combining innovation leaders to revolutionize aortic treatments | 10.26.15

  10. Slide 10: Deep Pipeline Addressing $3B+ Opportunity

    Combining innovation leaders to revolutionize aortic treatments | 10.26.15 U.S. Europe Asia Pacific Latin America Deep Pipeline Addressing $3B+ Opportunity* (post merger) 2015 2016 2017 2018 2019 2020 (Japan) (China) (Japan) (Brazil) (Argentina) (Japan) (Brazil, Argentina) CHEVAS CHEVAS CHEVAS THORA

  11. Slide 11: Transaction Overview

    Transaction Overview 1 Intrinsic value of TriVascular equity awards assumes a $10 Endologix share price, and will be paid to shareholders and is based on 2.3M options, 0.8M restricted stock units, and 0.4M warrants 2 Assumes redemption of TriVascular $10 million convertible debt, which will either b

  12. Slide 12: Creating a Leader in Growth and Innovation

    Creating a Leader in Growth and Innovation Increased revenue growth Broad AAA product line Expanded global sales force Significant clinical evidence Robust new product pipeline $30M+ synergies in 2017 and EBITDA accretive in 2018 Combining innovation leaders to revolutionize aortic treatments | 10.2

  13. Slide 13: Treat more patients more effectively

    Treat more patients more effectively

TriVascular Technologies — Merger or Acquisition (October 2015) on 6ix